INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage

Coverage Policy
Somatosensory evoked potentials (SSEPs) are considered medically necessary when prior diagnostic testing has failed to confirm a diagnosis for ANY of the following:
• coma • myoclonus • multiple sclerosis and other demyelinating diseases (e.g., adrenoleukodystrophy, adrenomyeloneuropathy, metachromatic leukodystrophy, and Pelizaeus-Merzbacher disease) • spinocerebellar degeneration • spinal cord trauma • subacute combined degeneration of the spinal cord (e.g., Lichtheim disease) • degenerative nontraumatic spinal cord lesions (e.g., cervical spondylotic myelopathy)
• syringomyelia • hereditary spastic paraplegia SSEPs are considered experimental, investigational or unproven for ANY other indication, including the evaluation of disorders of the lumbosacral roots, such as radiculopathies, thoracic root disorders, or cervical root disorders.
Overview
This Coverage Policy addresses somatosensory evoked potential testing performed outside the operative setting.
General Background
Somatosensory evoked potentials (SSEPs) are noninvasive studies performed by repetitive, submaximal, electrical stimulation of a sensory or mixed sensorimotor peripheral nerve used to aid in the determination of a diagnosis. SSEPs are an extension of the electrodiagnostic evaluation and are used to evaluate nerves that cannot be studied by conventional nerve conduction studies, including electromyography.
The evoked potential response depends on the functional integrity of the nerve that is stimulated. An abnormal SSEP points to a problem in the nerve conduction mechanism that carries the impulse to the brain, however, the SSEP abnormality is not disease specific-an abnormal SSEP indicates impairments associated with certain disorders. An abnormal SSEP signifies an impaired pathway, helps to localize it, and provides a prognostic guide. The SSEP does not provide any indication about the nature of the underlying pathological processes. Although evoked potentials offer additional information regarding function that can be clinically useful, magnetic resonance imaging (MRI) is often the preferred test to determine structural abnormalities and provides more specific information regarding neurologic structures.
SSEPs are altered by impairment of the somatosensory pathway which may occur as a result of both diffuse (e.g., diseases of myelin, hereditary system degenerations, coma) or local disorders (e.g., tumors, vascular lesions). SSEP abnormalities can be detected in a variety of different settings; therefore, the electrophysiologic findings should be interpreted in the clinical context in which they are obtained (e.g., assessing functional integrity, diagnostic purposes, determining the course of neurological disorders, determining pathological involvement). SSEPS are helpful in evaluating ill-defined complaints. A physician assesses the patient and determines a preliminary differential diagnosis; SSEP testing may then be performed by a trained technologist under the direct supervision of a trained electrodiagnostic physician. Direct supervision implies that a physician is in close proximity to the patient undergoing testing, is immediately available to provide the trained technician with assistance and direction if necessary, and is responsible for determining the SSEP studies that are appropriate.
Evoked potentials are used to assist in diagnosing ill-defined neurological conditions and to categorize afferent pathways that may be responsible for the resulting symptoms experienced by the patient. • spinal cord trauma • subacute combined degeneration • non traumatic spinal cord lesions (e.g., cervical spondylosis)
In addition, SSEPs are also useful to evaluate spinal compression associated with syringomyelia and for assessment of hereditary spastic paraplegia (AANEM, 1999).
SSEPs have been utilized to evaluate other peripheral nerve disorders such as acute inflammatory demyelinating polyradiculoneuropathy and focal neuropathies (e.g., entrapment neuropathies, carpal tunnel syndrome, lateral femoral cutaneous neuropathy, medial and lateral plantar neuropathy, saphenous neuropathy, intercostals neuropathy, trigeminal neuropathy, plexopathy) in addition to nerve root dysfunction (i.e., lumbosacral root [acute radiculopathies], thoracic root, cervical root). However, the diagnostic utility of SSEPs for these conditions remains controversial (AANEM, 1999). The AANEM reported that the available evidence is not convincing that SSEPs for these indications provide information that cannot be obtained with conventional nerve conduction studies or needle electromyography.
SSEPS are rarely used to assess peripheral neuropathy as standard nerve conduction velocity studies are the preferred test.
There are no data to suggest a role for SSEPs in the evaluation of behavioral health disorders. The usefulness of evoked potential testing in psychiatry, including SSEPs, is still under investigation (Guse and Love, 2005) .
Recordings of SSEP can be normal even in patients with extreme sensory deficits due to the presence of multiple parallel, afferent somatosensory pathways. This procedure is often performed to investigate patients with multiple sclerosis (MS); various coma states, such as those from post-traumatic injury or post-anoxia; suspected brain death; and to indicate the extensiveness of lesion damage in spinal cord injuries. The return or presence of a cortically-generated response to stimulation of a nerve below the injured portion of the cord indicates an incomplete lesion and therefore may offer a better prognosis.
SSEP testing is typically performed bilaterally. Depending on the clinical situation being investigated, several nerves in one extremity may have to be tested and compared with the opposite limb. The physician's SSEP report should indicate which nerves were tested, latencies at various testing points and an evaluation of whether the results were normal or abnormal.
Sensitivity and specificity reports for electrodiagnostic testing methods (in general) vary. A clearly established measure of comparison is lacking in the medical literature, making comparisons across studies difficult. Some studies have compared results with clinical examination findings, imaging studies such as magnetic resonance imaging, computed tomography, myelography, or the observation of nerve root compression during surgery. Interobserver differences, the variety of tests employed, the presence of symptoms that may influence patient outcomes (e.g., pain), the presence of abnormal imaging studies in asymptomatic patients, and the subjectivity of the surgeon's interpretations may all lead to variances in sensitivity and specificity results. Despite these variances however, electrodiagnostic testing is commonly used to assist in diagnosing disorders involving the nerves, muscles and neuromuscular junction. 2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement. Other spondylosis with myelopathy, occipito-atlanto-axial region M47. 12 Other spondylosis with myelopathy, cervical region M47. 13 Other spondylosis with myelopathy, cervicothoracic region M47. 14 Other spondylosis with myelopathy, thoracic region M47. 15 Other spondylosis with myelopathy, thoracolumbar region M47. 16 Other spondylosis with myelopathy, lumbar region M48. 21 Subluxation stenosis of neural canal of cervical region M99. 22 Subluxation stenosis of neural canal of thoracic region M99. 30 Osseous stenosis of neural canal of head region M99. 31 Osseous stenosis of neural canal of cervical region M99. 32 Osseous stenosis of neural canal of thoracic region M99. 40 Connective tissue stenosis of neural canal of head region M99. 41 Connective tissue stenosis of neural canal of cervical region M99.42
Considered Medically Necessary when criteria in the applicable
Connective tissue stenosis of neural canal of thoracic region M99.50
Intervertebral disc stenosis of neural canal of head region M99.51
Intervertebral disc stenosis of neural canal of cervical region M99.52
Intervertebral disc stenosis of neural canal of thoracic region M99.60
Osseous and subluxation stenosis of intervertebral foramina of head region M99.61
Osseous and subluxation stenosis of intervertebral foramina of cervical region M99.62
Osseous and subluxation stenosis of intervertebral foramina of thoracic region M99.70
Connective tissue and disc stenosis of intervertebral foramina of head region M99.71
Connective tissue and disc stenosis of intervertebral foramina of cervical region M99.72
Connective tissue and disc stenosis of intervertebral foramina of thoracic region P11. Glasgow coma scale score 9-12 R40.243
Glasgow coma scale score 3-8 S14.0XXA-S14.0XXS Concussion and edema of cervical spinal cord S14.101A-S14.109S
Other and unspecified injury of cervical spinal cord S14.111A-S14.119S
Complete lesion of cervical spinal cord S14.121A-S14.129S 
